Oric Pharmaceuticals, Inc. (ORIC)

Pharmaceutical Preparations · market cap $1.4B · as of 2026-07-20

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-12 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Oric Pharmaceuticals (ORIC) is a clinical-stage oncology biotech with 106 employees and a ~$1.1B market cap, built almost entirely around ORIC-114, a Phase 2 solid tumor asset of undisclosed mechanism. The company carries no revenue, burns roughly $110M annually in R&D, and as of mid-2026 holds only $56.4M in cash — implying a runway of approximately five months without additional financing.

The catalyst path

2026-11-12 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
ORIC-114	Phase 2	Solid Tumors
Rinzimetostat	Phase 3	Metastatic Castration Resistant Prostate Cancer

Price & technical context

3-month

+14.8%

6-month

+40.8%

12-month

+6.9%

52-wk range

$7.47–$14.65

vs 50-day MA

-3.5%

vs 200-day MA

+15.5%

Realized vol

90.5%

Max drawdown

-66.0%

Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for ORIC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.